IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.62
+3.33%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 159.89x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 7.76x
- Price / sales
- 804.09x
- Price / cash flow
- -13.77x
Enterprise value
- Enterprise value
- $4.9B
- EV / sales
- 691.64x
- EV / EBITDA
- -9.11x
- EV / EBIT
- -8.78x
- Market cap
- $5.7B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026